Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials
Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million. With the increasing number of deaths, it is urgent to find...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.971890/full |
| _version_ | 1828148319738658816 |
|---|---|
| author | Zhenchao Wu Zhenchao Wu Zhifei Han Zhifei Han Beibei Liu Beibei Liu Ning Shen Ning Shen |
| author_facet | Zhenchao Wu Zhenchao Wu Zhifei Han Zhifei Han Beibei Liu Beibei Liu Ning Shen Ning Shen |
| author_sort | Zhenchao Wu |
| collection | DOAJ |
| description | Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million. With the increasing number of deaths, it is urgent to find effective treatment drugs. Remdesivir, an investigational broad-spectrum antiviral drug produced by Gilead has been shown to inhibit SARS-CoV-2, in vitro and in vivo. This review is aimed to analyze the feasibility of remdesivir in COVID-19 and put forward the shortcomings of present clinical studies. We systematically searched PubMed and Web of Science up until 24 May 2022, using several specific terms such as “remdesivir” or “GS-5734” and “COVID-19” or “SARS-CoV-2” and retrieved basic researches and clinical studies of remdesivir in COVID-19. In this review, we summarized and reviewed the mechanism of remdesivir in SARS-COV-2, clinical trials of using remdesivir in COVID-19, analyzed the efficacy and safety of remdesivir, and judged whether the drug was effective for the treatment of COVID-19. In different clinical trials, remdesivir showed a mixed result in the treatment of COVID-19. It seemed that remdesivir shortened the time to recovery and had an acceptable safety profile. However, more clinical trials are needed to test the efficacy and safety of remdesivir. |
| first_indexed | 2024-04-11T21:14:12Z |
| format | Article |
| id | doaj.art-ca23611ff4b54a0995696be727f66735 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T21:14:12Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-ca23611ff4b54a0995696be727f667352022-12-22T04:02:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-09-011310.3389/fphar.2022.971890971890Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trialsZhenchao Wu0Zhenchao Wu1Zhifei Han2Zhifei Han3Beibei Liu4Beibei Liu5Ning Shen6Ning Shen7Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, ChinaCenter for Infectious Diseases, Peking University Third Hospital, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, ChinaSchool of Basic and Clinical Medicine, Shandong First Medical University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, ChinaCenter for Infectious Diseases, Peking University Third Hospital, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, ChinaCenter for Infectious Diseases, Peking University Third Hospital, Beijing, ChinaSince December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million. With the increasing number of deaths, it is urgent to find effective treatment drugs. Remdesivir, an investigational broad-spectrum antiviral drug produced by Gilead has been shown to inhibit SARS-CoV-2, in vitro and in vivo. This review is aimed to analyze the feasibility of remdesivir in COVID-19 and put forward the shortcomings of present clinical studies. We systematically searched PubMed and Web of Science up until 24 May 2022, using several specific terms such as “remdesivir” or “GS-5734” and “COVID-19” or “SARS-CoV-2” and retrieved basic researches and clinical studies of remdesivir in COVID-19. In this review, we summarized and reviewed the mechanism of remdesivir in SARS-COV-2, clinical trials of using remdesivir in COVID-19, analyzed the efficacy and safety of remdesivir, and judged whether the drug was effective for the treatment of COVID-19. In different clinical trials, remdesivir showed a mixed result in the treatment of COVID-19. It seemed that remdesivir shortened the time to recovery and had an acceptable safety profile. However, more clinical trials are needed to test the efficacy and safety of remdesivir.https://www.frontiersin.org/articles/10.3389/fphar.2022.971890/fullremdesivirCOVID-19SARS-CoV-2clinical trialsefficacysafety |
| spellingShingle | Zhenchao Wu Zhenchao Wu Zhifei Han Zhifei Han Beibei Liu Beibei Liu Ning Shen Ning Shen Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials Frontiers in Pharmacology remdesivir COVID-19 SARS-CoV-2 clinical trials efficacy safety |
| title | Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials |
| title_full | Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials |
| title_fullStr | Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials |
| title_full_unstemmed | Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials |
| title_short | Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials |
| title_sort | remdesivir in treating hospitalized patients with covid 19 a renewed review of clinical trials |
| topic | remdesivir COVID-19 SARS-CoV-2 clinical trials efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.971890/full |
| work_keys_str_mv | AT zhenchaowu remdesivirintreatinghospitalizedpatientswithcovid19arenewedreviewofclinicaltrials AT zhenchaowu remdesivirintreatinghospitalizedpatientswithcovid19arenewedreviewofclinicaltrials AT zhifeihan remdesivirintreatinghospitalizedpatientswithcovid19arenewedreviewofclinicaltrials AT zhifeihan remdesivirintreatinghospitalizedpatientswithcovid19arenewedreviewofclinicaltrials AT beibeiliu remdesivirintreatinghospitalizedpatientswithcovid19arenewedreviewofclinicaltrials AT beibeiliu remdesivirintreatinghospitalizedpatientswithcovid19arenewedreviewofclinicaltrials AT ningshen remdesivirintreatinghospitalizedpatientswithcovid19arenewedreviewofclinicaltrials AT ningshen remdesivirintreatinghospitalizedpatientswithcovid19arenewedreviewofclinicaltrials |